BioCryst Pharmaceuticals
BCRX
115 hedge funds and large institutions have $384M invested in BioCryst Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 27 reducing their positions, and 16 closing their positions.
212% more call options, than puts
Call options by funds: $6.27M | Put options by funds: $2.01M
67% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 27
1.67% more ownership
Funds ownership: 84.22% → 85.89% (+1.7%)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
2% less funds holding
Funds holding: 117 → 115 (-2)
32% less capital invested
Capital invested by funds: $568M → $384M (-$184M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.97M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.07M |
| 5 |
Millennium Management
New York
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VMI
VHCP Management II
New York
|
-$21.9M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$9.06M |
| 3 |
D.E. Shaw & Co
New York
|
-$6.49M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$5.03M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.58M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CSS
126
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$118K | -14,016 | Closed |
|
|
QSS
127
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
| – | -$115K | -13,631 | Closed |
|
|
TSS
128
Two Sigma Securities
New York
| – | -$87K | -10,396 | Closed |
|
129
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$8K | -1,000 | Closed |
|
|
PCM
130
Prelude Capital Management
New York
| – | -$7K | -800 | Closed |
|
BCRX Hedge Fund Activity: Q2 2017 in Review
115 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2017, worth a combined $384M — down 32% from $568M a quarter earlier.
Fund positioning in BCRX was balanced in Q2 2017: 16 funds opened new positions, 16 closed out, 45 added to existing stakes and 27 trimmed.
The largest buyer was RA Capital Management, adding an estimated $10.2M. The largest seller was VHCP Management II, cutting an estimated $21.9M.
- 115 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2017, down from 117 in Q1 2017.
- Funds reported $384M of BioCryst Pharmaceuticals stock for Q2 2017, down 32% quarter-over-quarter.
- 16 funds opened new BioCryst Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of 0 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2017 was RA Capital Management, an estimated $10.2M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2017 was VHCP Management II, an estimated $21.9M sold.
Based on aggregated 13F filings for Q2 2017.